OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:33 UTC. Every row links to its source record.

PPM1D protein phosphatase, Mg2+/Mn2+ dependent 1D

ENSG00000170836 · protein coding · Open Targets profile

Involved in the negative regulation of p53 expression (PubMed:23242139). Required for the relief of p53-dependent checkpoint mediated cell cycle arrest. Binds to and dephosphorylates 'Ser-15' of TP53 and 'Ser-345' of CHEK1 which contributes to the functional inactivation of these proteins (PubMed:15870257, PubMed:16311512). Mediates MAPK14 dephosphorylation and inactivation (PubMed:21283629). Is also an important regulator of global heterochromatin silencing and critical in maintaining genome integrity (By similarity). {ECO:0000250|UniProtKB:Q9QZ67, ECO:0000269|PubMed:15870257, ECO:0000269|PubMed:16311512, ECO:0000269|PubMed:21283629, ECO:0000269|PubMed:23242139}.

In 13 of 15 cancers, the evidence for PPM1D comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751hereditary breast carcinomahereditary breast carcinomahereditary breast carcinoma: germline 0.84ovarian carcinomaovarian carcinomaovarian carcinoma: somatic 0.61malignant gliomamalignant gliomamalignant glioma: somatic 0.61colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.61essential thrombocythemiaessential thrombocythemiaessential thrombocythemia: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61HER2 positive breast carcinomaHER2 positive breast carcinomaHER2 positive breast carcinoma: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61pilocytic astrocytomapilocytic astrocytomapilocytic astrocytoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61Brain Stem GlioblastomaBrain Stem GlioblastomaBrain Stem Glioblastoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61ovarian cancerovarian cancerovarian cancer: germline 0.41acute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
High-Quality Ligand
PROTAC
Database Ubiquitination, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.8918399810791016 (upper bound 1.1236000061035156). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of PPM1D's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of PPM1D's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.